Scharf Investments LLC reduced its position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 21.1% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,076,520 shares of the medical equipment provider's stock after selling 555,004 shares during the quarter. Smith & Nephew SNATS accounts for about 1.8% of Scharf Investments LLC's investment portfolio, making the stock its 22nd biggest holding. Scharf Investments LLC owned 0.47% of Smith & Nephew SNATS worth $58,911,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. Principal Securities Inc. increased its position in shares of Smith & Nephew SNATS by 87.6% during the fourth quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider's stock valued at $36,000 after acquiring an additional 691 shares in the last quarter. National Bank of Canada FI increased its holdings in shares of Smith & Nephew SNATS by 36.5% in the 4th quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider's stock worth $41,000 after purchasing an additional 446 shares in the last quarter. Hara Capital LLC increased its holdings in shares of Smith & Nephew SNATS by 391.4% in the 4th quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider's stock worth $60,000 after purchasing an additional 1,957 shares in the last quarter. Opal Wealth Advisors LLC bought a new stake in shares of Smith & Nephew SNATS in the 1st quarter worth $73,000. Finally, GAMMA Investing LLC increased its holdings in shares of Smith & Nephew SNATS by 22.4% in the 1st quarter. GAMMA Investing LLC now owns 3,641 shares of the medical equipment provider's stock worth $103,000 after purchasing an additional 666 shares in the last quarter. 25.64% of the stock is currently owned by institutional investors.
Smith & Nephew SNATS Stock Performance
NYSE SNN traded up $0.30 during trading hours on Thursday, hitting $30.20. 853,866 shares of the company's stock traded hands, compared to its average volume of 815,389. The business's fifty day moving average price is $28.58 and its two-hundred day moving average price is $27.06. The company has a current ratio of 2.89, a quick ratio of 1.33 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $13.23 billion, a P/E ratio of 13.98, a P/E/G ratio of 0.92 and a beta of 0.68. Smith & Nephew SNATS, Inc. has a 52 week low of $23.69 and a 52 week high of $31.72.
Analyst Ratings Changes
Several equities research analysts recently commented on the company. Canaccord Genuity Group lifted their price objective on Smith & Nephew SNATS from $27.00 to $28.00 and gave the stock a "hold" rating in a report on Thursday, May 1st. HSBC lowered shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research note on Friday, April 25th. Wall Street Zen raised shares of Smith & Nephew SNATS from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, February 26th. Hsbc Global Res downgraded shares of Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Finally, UBS Group lowered Smith & Nephew SNATS from a "buy" rating to a "neutral" rating in a report on Wednesday, March 12th. Six analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Smith & Nephew SNATS has a consensus rating of "Hold" and a consensus target price of $28.00.
Read Our Latest Analysis on Smith & Nephew SNATS
About Smith & Nephew SNATS
(
Free Report)
Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.
Featured Stories
Before you consider Smith & Nephew SNATS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew SNATS wasn't on the list.
While Smith & Nephew SNATS currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
